CTOs on the Move

Cullgen

www.cullgen.com

 
Cullgen is a privately held biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.cullgen.com
  • 12671 High Bluff Drive Suite 130
    San Diego, AK USA 92130
  • Phone: 858.284.0115

Executives

Name Title Contact Details

Funding

Cullgen raised $16M on 04/10/2019
Cullgen raised $50M on 02/25/2021

Similar Companies

CovX Research

CovX Research is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TrovaGene

Trovagene is a molecular diagnostics company providing precise, noninvasive urine and blood testing for detecting and monitoring oncogene mutations. By utilizing proprietary technology that analyzes circulating tumor DNA, Trovagene testing offers critical data that may help inform cancer treatment decisions, giving physicians and patients monitoring options beyond biopsy or imaging.

Suitx

suitX develops robotic exoskeletons for the medical and industrial markets. The Phoenix is the world`s lightest and most advanced medical exoskeleton designed to help people with mobility disorders to be upright and mobile. MAX (Modular Agile Exoskeleton) increases productivity while decreasing the risk of injury by reducing muscle strain on employees working in an industrial setting.

iCyt Mission Technology

iCyt Mission Technology is a Champaign, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Invivyd

Invivyd is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. ​​Invivyd`s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications.